ASMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Assembly Biosciences Inc (ASMB) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as hedge fund interest and an increased price target from analysts, the financial performance shows declining net income and EPS, which are critical for long-term growth. Additionally, technical indicators suggest a neutral to slightly bearish trend, and there are no strong trading signals or recent news to act as a catalyst. Given the investor's preference for long-term stability, it is better to hold off on buying this stock until stronger financial performance or clearer positive trends emerge.
The MACD is positive but contracting, RSI is neutral at 40.341, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 25.07), but overall technical indicators suggest a neutral to slightly bearish trend.
Hedge funds are increasing their buying activity significantly (161.98% increase in the last quarter). Analyst Salim Syed from Mizuho raised the price target to $40 from $29, reflecting confidence in the company's recent positive ABI-5366 data.
The stock has shown a regular market decline of -4.64% and is projected to have a slight negative trend in the short term (-0.3% in the next week, -0.85% in the next month). No recent news or congress trading data to act as a catalyst.
In Q3 2025, revenue increased by 57.62% YoY to $10,789,000, but net income dropped by 4.34% YoY to -$9,196,000, and EPS declined significantly by 52.32% YoY to -$0.72. Gross margin remained stable at 100%.
Mizuho analyst Salim Syed raised the price target to $40 from $29 and maintained an Outperform rating, citing positive ABI-5366 data.
